Koers Diaxonhit Euronext Paris
Aandelen
FR0004054427
Biotechnologie & Medisch Onderzoek
Omzet 2023 | 130 mln. 139 mln. | Omzet 2024 * | 138 mln. 147 mln. | Marktkapitalisatie | 145 mln. 155 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2023 | 4 mln. 4,27 mln. | Nettowinst (verlies) 2024 * | 9 mln. 9,61 mln. | EV/omzet 2023 | 1,29 x |
Nettoschuld 2023 * | 8,8 mln. 9,4 mln. | Nettoliquiditeiten 2024 * | 9,9 mln. 10,57 mln. | EV/omzet 2024 * | 0,98 x |
K/w-verhouding 2023 |
38,3
x | K/w-verhouding 2024 * |
15
x | Werknemers | - |
Dividendrendement 2023 * |
-
| Dividendrendement 2024 * |
-
| Vrij verhandelbaar | 59,14% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19-06-17 |
Director of Finance/CFO | 43 | 01-10-22 | |
Cathie Marsais
COO | Chief Operating Officer | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Denis Fortier
CEO | Chief Executive Officer | - | 19-06-17 |
Director/Board Member | 68 | 04-11-09 | |
Director/Board Member | 67 | 15-06-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+0,44% | 42,86 mld. | |
+12,34% | 42,74 mld. | |
+44,30% | 41,36 mld. | |
-6,20% | 27,68 mld. | |
+5,83% | 25,15 mld. | |
-23,42% | 18,63 mld. | |
+28,22% | 12,37 mld. | |
-3,60% | 11,92 mld. | |
+6,64% | 11,21 mld. |